Literature DB >> 28273011

Imatinib Changed Everything.

Dan L Longo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28273011     DOI： 10.1056/NEJMe1700833

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Authors:  Alice Giustacchini; Supat Thongjuea; Nikolaos Barkas; Petter S Woll; Benjamin J Povinelli; Christopher A G Booth; Paul Sopp; Ruggiero Norfo; Alba Rodriguez-Meira; Neil Ashley; Lauren Jamieson; Paresh Vyas; Kristina Anderson; Åsa Segerstolpe; Hong Qian; Ulla Olsson-Strömberg; Satu Mustjoki; Rickard Sandberg; Sten Eirik W Jacobsen; Adam J Mead
Journal:  Nat Med       Date:  2017-05-15       Impact factor: 53.440

Review 2.  Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Jason Gotlib; Ruben Mesa; Steffen Koschmieder; H Jean Khoury; Jorge E Cortes; Tiziano Barbui; Rüdiger Hehlmann; Michael Mauro; Susanne Saussele; Jerald P Radich; Richard A Van Etten; Giuseppe Saglio; Srdnan Verstovek; Robert Peter Gale; Omar Abdel-Wahab
Journal:  Leuk Res       Date:  2018-02-14       Impact factor: 3.156

Review 3.  The Cure of Chronic Myeloid Leukemia: Are We There Yet?

Authors:  Tapan Saikia
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

4.  Precision Dosing of Targeted Therapies Is Ready for Prime Time.

Authors:  Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer
Journal:  Clin Cancer Res       Date:  2021-09-21       Impact factor: 12.531

5.  Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Authors:  Yue Zhan; Xiaolei Zhou; Sylvain Peuget; Madhurendra Singh; Brian D Peyser; Zhimin Fan; Galina Selivanova
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

6.  Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.

Authors:  Iva Gudernova; Lukas Balek; Miroslav Varecha; Jana Fialova Kucerova; Michaela Kunova Bosakova; Bohumil Fafilek; Veronika Palusova; Stjepan Uldrijan; Lukas Trantirek; Pavel Krejci
Journal:  Oncotarget       Date:  2017-11-27

7.  Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Chun-Jun Li; Jia Chen; Yu-Zhou Qin; Jian-Si Chen; Wei-Zhong Tang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

8.  Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.

Authors:  Alba Rodriguez-Meira; Gemma Buck; Sally-Ann Clark; Benjamin J Povinelli; Veronica Alcolea; Eleni Louka; Simon McGowan; Angela Hamblin; Nikolaos Sousos; Nikolaos Barkas; Alice Giustacchini; Bethan Psaila; Sten Eirik W Jacobsen; Supat Thongjuea; Adam J Mead
Journal:  Mol Cell       Date:  2019-02-12       Impact factor: 17.970

Review 9.  Single cell analysis of normal and leukemic hematopoiesis.

Authors:  Benjamin J Povinelli; Alba Rodriguez-Meira; Adam J Mead
Journal:  Mol Aspects Med       Date:  2017-09-08

10.  In Silico Screening for Novel Leucine Aminopeptidase Inhibitors with 3,4-Dihydroisoquinoline Scaffold.

Authors:  Joanna Ziemska; Jolanta Solecka; Małgorzata Jarończyk
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.